J&J investment to develop stem cell products

Johnson & Johnson has made a cash injection into an innovative phase two stem cell clinical trial programme.

Capricor Therapeutics is to collaborate with Janssen Biotech, a wholly-owned subsidiary of J&J, to develop regenerative cell therapies, including Capricor’s lead product, CAP-1002 – a cardiac-derived stem cell product.

“One of the reasons why I was motivated to work on this deal is because of the statement it makes in the field.

“It says, OK, somebody very large and powerful is taking a look at this technology and saying there’s something there, and that’s the most exciting thing for me.”

Linda Marban, chief executive, Capricor Therapeutics, reported by FierceBiotech.



Related news:

Capricor gets $12.5M upfront payment in Janssen development agreement (Yahoo! Finance).

J&J gambles $12.5M in rare Big Pharma bet on a stem cell therapy (FierceBiotech)

Reference link:

Clinical trials of cardiac derived cells (Capricor website)

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.